{
}
Roche is considering seeking accelerated U.S. approval for its Alzheimer’s drug trontinemab, which shows promise in significantly lowering amyloid protein levels linked to cognitive decline. Early Phase 2 data indicates it may clear amyloid more quickly than competitors, with fewer side effects like ARIA. The company plans to expand its trial to 120 participants while adjusting safety criteria after a related incident.
Eli Lilly's stock plummeted nearly 10% in premarket trading after the company reported Q3 earnings that fell short of Wall Street expectations, with revenue at $11.4 billion against estimates of $12.17 billion. Despite a 20% year-over-year increase, the company cut its profit guidance and revenue outlook, citing inventory decreases impacting sales of its weight-loss drug Zepbound and diabetes drug Mounjaro. The combined sales from these drugs reached $4.4 billion, but Zepbound's revenue missed analyst estimates, raising concerns about the stock's future in a complex healthcare market.
The drug and biotech sector is experiencing a strong earnings season, highlighted by Johnson & Johnson's recent performance, which exceeded estimates and led to an upward revision of revenue expectations. Five large drug companies—Novo Nordisk, Novartis, Pfizer, Regeneron Pharmaceuticals, and Biogen—are anticipated to outperform in their upcoming quarterly results, with Novo Nordisk showing a positive Earnings ESP of +1.02% and a Zacks Rank #3. Overall, the Medical sector is projected to see a 6.4% rise in fourth-quarter earnings and an 8.5% increase in revenues.
Biogen
People
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
Roche considers accelerated approval for promising Alzheimer’s drug trontinemab
United States Dollar
Biogen Inc.
Eisai Co., Ltd.
Eli Lilly and Company
Hoffmann-La Roche AG
CHE
Eli Lilly
Hanno Svoboda
Biogen
Eisai
Show more
22:44 31.10.2024
eli lilly shares drop after disappointing third quarter earnings report
United States Dollar
Biogen Inc.
Eisai Co., Ltd.
Eli Lilly and Company
USA
Leqembi
Jared Holz
Biogen
Show more
12:18 30.10.2024
large drug stocks poised to exceed q3 earnings expectations
Novartis AG
Novo Nordisk A/S
Biogen Inc.
Pfizer Inc.
Regeneron Pharmaceuticals, Inc.
DNK
Regeneron Pharmaceuticals
Novo Nordisk
Biogen
Novartis
Pfizer
Show more
14:31 22.10.2024
Trending
Subcategory
Startups & Entrepreneurship
Corporate News
Industry Trends
Global Trade Developments
Government Economic Policies
Stock Market Updates
Retail and Consumer Goods
Industry Mergers & Acquisitions
Supply Chain Management
Global Financial Events
Venture Capital Investments
Private Equity Deals
Workplace Trends
Market Analysis and Predictions
Cryptocurrency & Blockchain Regulations
Funding Rounds & Investments
Finance Mergers & Acquisitions
Central Bank Actions
Energy Sector Developments
Inflation and Monetary Impact
Countries:
Companies:
Apple Inc.
NVIDIA Corporation
Google Inc.
Samsung Securities Co.,Ltd.
Microsoft Corporation
Taiwan Semiconductor Manufacturing Company Limited
Verizon Communications Inc.
OpenAI ERC USD
The Goldman Sachs Group, Inc.
Dell Technologies Inc.
European Union Bonds
BRAINBEES SOLUTIONS LTD
Eternal Limited
CarTrade Tech Limited
PB Fintech Limited
OLA ELECTRIC MOBILITY LTD
KuCoin Token USD
CANVAS N Co.,Ltd.
Baidu, Inc.
iFLYTEK CO.,LTD
Currencies:
United States Dollar
Euro
Chinese Yuan
Indian Rupee
Japanese Yen
British Pound Sterling
Australian Dollar
New Zealand Dollar
Vietnamese Đồng
South Korean Won
Egyptian Pound
New Taiwan Dollar
Indonesian Rupiah
South African Rand
United Arab Emirates Dirham
Malaysian Ringgit
Singapore Dollar
Lebanese Pound
People:
Donald Trump
Howard Lutnick
Shigeru Ishiba
Scott Bessent
Jamieson Greer
Abdulaziz bin Salman Al Saud
Mohammad Al Tamimi
Mohammad Altamimi
Jensen Huang
Sam Altman
Xi Jinping
Chris Wright
Christopher Flinos
Mohammed bin Salman Al Saud
John Abraham
Swaminathan Aiyar
Todd Blanche
Justin Sun
Changpeng Zhao
Cameron Adams